Astellas and Audax Forge $1.34B Immuno-Oncology Deal
Big Moves in Immuno-Oncology: Astellas' Latest Bet You hear 'immuno-oncology,' you think breakthrough, right? Well, friends, that's what Astellas and Audax Biosciences are shooting for with their fresh handshake over DAX-044. On October 27, 2026, in Tokyo and Melbourne, the two outfits announced they're joining forces to bring this novel immunotherapy to the table. It's...
Continue Reading